ホーム>>Signaling Pathways>> Stem Cell>> GSK-3>>Indirubin-5-sulfonate

Indirubin-5-sulfonate

カタログ番号GC36313

インジルビン-5-スルホネートは、CDK1/サイクリン B、CDK2/サイクリン A、CDK2/サイクリン E の IC50 値が 55 nM、35 nM、150 nM、300 nM、65 nM のサイクリン依存性キナーゼ (CDK) 阻害剤です。それぞれ CDK4/サイクリン D1、および CDK5/p35。インジルビン-5-スルホネートは、GSK-3β に対しても阻害活性を示します。

Products are for research use only. Not for human use. We do not sell to patients.

Indirubin-5-sulfonate 化学構造

Cas No.: 244021-67-8

サイズ 価格 在庫数 個数
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively[1]. Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β[2]. Cdk1/cyclin B|55 nM (IC50)|cdk2/cyclin A|35 nM (IC50)|CDK2/cyclinE|150 nM (IC50)|Cdk4/cyclin D1|300 nM (IC50)|CDK5/p35|65 nM (IC50)|GSK-3β

[1]. Hoessel R, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999 May;1(1):60-7. [2]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors• J Biol Chem. 2001 Jan 5;276(1):251-60.

レビュー

Review for Indirubin-5-sulfonate

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Indirubin-5-sulfonate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.